Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory ...
5h
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
20hon MSN
We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
Stocktwits on MSN9h
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...
The Targeted Pulse: New Trial Evaluating Iadademstat/Azacitidine in MDS and Positive Trends in HNSCC
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback